

Special Issue

Streptococcal Vaccines: Current Status and Future Directions

Message from the Guest Editor

Streptococcal infections are among the most common bacterial infections. Among Streptococcal species, three are of significant concern: (a) Group B Streptococcus (GBS), causing serious infections like pneumonia, sepsis, and meningitis; (b) *Streptococcus pneumoniae*, causing a common community-acquired pneumonia, particularly in young children and the elderly; and (c) Group A Streptococcus (GAS), causing strep throat, skin and bloodstream infections, and deadly rheumatic heart diseases. Vaccines against *S. pneumoniae* are available (e.g., Prevenar 13, Pneumovax 23); however, they do not offer universal protection, while vaccines against other *streptococci* are in development. Given the global spread, growing antibiotic resistance, and high mortality rate related to systemic infections and autoimmune postinfection complications, the need for the development of vaccines against these bacteria is of high priority.

- Vaccine development against Group A or B Streptococcus;
- Vaccines targeting other *Streptococcal* species;
- Adjuvants in streptococcal vaccines;
- Animal models for streptococcal vaccines;
- Clinical trials on the Streptococcal vaccines.

Guest Editor

Dr. Mariusz Skwarczynski

School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, QLD 4072, Australia

Deadline for manuscript submissions

31 July 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/249220

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).